^
Association details:
| Biomarker: | MCL1 overexpression |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + Mekinist (trametinib) (MEK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B cell malignancies
Published date:
12/03/2021
Excerpt:
To test if sensitivity could be detected in other B cell malignancies, we performed drug testing on cell line models of CLL (n=4), multiple myeloma (MM) (n=8) and mantle cell lymphoma (MCL) (n=7)....We found that high expression of the anti-apoptotic proteins myeloid cell leukemia-1 (Mcl-1) or B-cell lymphoma-extra large (Bcl-xL) predicted low sensitivity to trametinib + venetoclax.
DOI:
10.1002/1878-0261.13153
